MEU
0.11
54.9%
SPQ
0.008
-27.3%
HCF
0.027
50%
NES
0.006
-25%
CHM
0.004
33.3%
FBR
0.004
-20%
AXI
0.017
30.8%
MOH
0.008
-20%
MRQ
0.005
25%
NOR
0.013
-18.8%
TYX
0.005
25%
TRU
0.014
-17.6%
STV
0.011
22.2%
AYT
0.005
-16.7%
BLU
0.006
20%
A11
0.165
-15.4%
BNL
0.006
20%
M4M
0.006
-14.3%
MGU
0.006
20%
NFL
0.12
-14.3%
ALV
0.078
18.2%
RGL
0.006
-14.3%
TSK
0.13
18.2%
SER
0.006
-14.3%
GLL
0.007
16.7%
TEM
0.006
-14.3%
LKE
0.091
15.2%
CP8
0.065
-13.3%
PL9
0.008
14.3%
CC9
0.15
-11.8%
GIB
0.058
13.7%
SBM
0.497
-11.3%
FEX
0.492
13.1%
BMR
0.235
-11.3%
RRE
0.26
13%
ATH
0.008
-11.1%
TLM
0.13
13%
BMG
0.016
-11.1%
ARC
0.105
12.9%
MQR
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747